Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus, with revenue of $45.7M exceeding expectations by 13.8% and gross margin reaching 55% against an 8.0% estimate. The launch of AUCATZYL® drove a 119% YoY revenue increase, supported by expansion in authorized treatment centers. Management raised FY26 net product revenue guidance to $140M-$150M and secured a $250M credit facility, extending the cash runway into Q2 2028.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Autolus Therapeutics(AUTL) the Revenue is 45.69 M (+118.4%), Beat estimate;the EBIT is -43.84 M (+28.39%), Beat estimate;the EPS is -0.15 (+16.67%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.05B118.37%
0.04B91.90%
+0.01B26.47%
EBITExceed expectations
-0.04B28.39%
-0.05B21.55%
+0.00B6.84%
EPSExceed expectations
-0.1516.67%
-0.18834.63%
+0.038321.30%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf